At this stage, the combination of immune checkpoint inhibition therapy with targeted drugs such as EGFR-TKIs 33 or platinum-agent chemotherapy is a popular way of combining therapies for intermediate to advanced NSCLC 34. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.